EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma

Alex Horowitz, Claire Shen, Dominic J Vitello, Madison Cox, Amy Wells, Krishay Sridalla iD, David J Bentrem, Qiang Zhang, Ishan Roy, Akhil Chawla

Journal of Surgical Oncology · 2026

DOI: 10.1002/jso.70296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Alex Horowitz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Elsa U. Pardee Foundation and NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives To evaluate the prognostic significance of baseline and longitudinal changes in prognostic nutritional index (PNI) in localized pancreatic ductal adenocarcinoma (PDAC) and to assess the complementary prognostic value of PNI with tumor burden measured by circulating tumor DNA (ctDNA).

Methods

We analyzed 127 patients with localized PDAC enrolled in a prospective biomarker study (2020–2024). Laboratory values were collected at five standardized timepoints. PNI was calculated as (10 × albumin) + (0.005 × lymphocyte count). KRAS ctDNA was assessed using digital droplet PCR. The primary endpoint was overall survival (OS), analyzed using Kaplan–Meier and Cox regression, with longitudinal changes assessed using Friedman testing.

Results

Low PNI (< 45) at diagnosis was associated with worse OS ( p = 0.043). PNI declined significantly across treatment timepoints ( p < 0.001). In multivariable analysis, decline in PNI during neoadjuvant chemotherapy independently predicted worse OS (HR 1.095, 95% CI 1.042–1.152, p < 0.001). Patients with both low PNI and ctDNA positivity had a 3.64‐fold increased risk of death (HR 3.64, 95% CI 1.32–10.04, p = 0.012).

Conclusions

PNI is a dynamic, clinically accessible biomarker that independently predicts survival in localized PDAC. Integration of PNI with ctDNA improves prognostic stratification by capturing both patient host vulnerability and tumor burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCirculating Tumor DNABiomarkers, TumorNutrition AssessmentHumansFemaleMalePrognosisProspective StudiesAgedMiddle AgedSurvival RateNeoadjuvant TherapyFollow-Up Studies

Stichwörter der Autor:innen

biomarkercirculating tumor DNAneoadjuvant chemotherapypancreatic ductal adenocarcinomaprognostic nutritional index

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Division of Surgical Oncology, Chicago, Illinois, USA.
  • Northwestern Quality Improvement, Research & Education in Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Northwestern Medicine Cancer Centers, Northwestern Medicine Regional Medical Group, Winfield, Illinois, USA.
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
  • Circulating Tumor Cell Core Facility, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

ORCID-Profile: Krishay Sridalla

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • Elsa U. Pardee Foundation and NIH
  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Horowitz, A., Shen, C., Vitello, D. J., Cox, M., Wells, A., Sridalla, K., Bentrem, D. J., Zhang, Q., Roy, I., & Chawla, A. (2026). Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70296

Vancouver

Horowitz A, Shen C, Vitello DJ, Cox M, Wells A, Sridalla K, et al. Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70296

BibTeX
@article{Horowitz2026,
  author = {Horowitz, Alex and Shen, Claire and Vitello, Dominic J and Cox, Madison and Wells, Amy and Sridalla, Krishay and Bentrem, David J and Zhang, Qiang and Roy, Ishan and Chawla, Akhil},
  title = {Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70296}
}
Kostenlos starten →